IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.
JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 538-538
Erscheinungsjahr: 2023
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Kudo, Masatoshi (Autor)
Tsuchiya, Kaoru (Autor)
Shao, Yu Yun (Autor)
Finn, Richard S. (Autor)
Galle, Peter R. (Autor)
Ducreux, Michel (Autor)
Cheng, Ann-Lii (Autor)
Yamashita, Tatsuya (Autor)
Koga, Hironori (Autor)
Aoki, Kenichi (Autor)
Yamada, Kyoko (Autor)
Asakawa, Takashi (Autor)
Nakagawa, Yuki (Autor)
Ikeda, Masafumi (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
